In Reply We thank the Rahmoune et al for their comments and critical reading of our article.1 However, we respectfully disagree with the authors that analyzing antibodies against deamidated gliadin peptides (DGP) would have changed the outcome for detecting celiac disease in our study population of genetically at-risk children.
It is true that the DGP antibody assay may also detect children younger than 2 years who are IgA–tissue transglutaminase (TTG) negative with very early onset of celiac disease.2 However, most of these previous studies are retrospectively analyzed using clinical material already selected owing to being IgA-TTG or endomysial antibody positive, resulting in a falsely high diagnostic specificity.
Agardh D, Liu E, Triplett EW. Efficiency of Deamidated Gliadin Peptides for Screening Celiac Disease Autoimmunity—Reply. JAMA Pediatr. 2018;172(5):497. doi:10.1001/jamapediatrics.2018.0041
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: